Education
About Us
Working with TipRanks
Follow Us
Irhythm Technologies (IRTC)
NASDAQ:IRTC
Top Page
Irhythm Technologies
(NASDAQ:IRTC)
Select Model
Select Model
Rating:51Neutral
Price Target:
$115.00
▼(-1.10% Downside)
Action:ReiteratedDate:03/13/26
The score is held back primarily by balance-sheet leverage and continued full-year net losses, despite improving operating trajectory and a strong 2025 cash-flow inflection. Technicals are bearish with the stock well below key moving averages and negative MACD. Offsetting these, the latest earnings call was constructive with guidance for continued growth and margin/free-cash-flow expansion, but execution and regulatory risks (including the delayed next-gen MCT) remain.
Positive Factors
Market leadership in long‑term monitoring
A dominant ~72% share in long‑term continuous monitoring, backed by clinical credibility and >135 scientific publications, creates a durable moat. High clinician adoption and entrenched workflows make volume and referral patterns sticky, supporting recurring study throughput and pricing leverage.
Improving cash generation and margins
Material swing to positive operating and free cash flow in 2025 signals a structural improvement in cash generation capacity. Sustained FCF supports debt servicing, R&D and commercialization without immediate external financing, reducing funding risk as margins continue to expand from robust gross margins.
Large proprietary ECG dataset and AI capability
A vast, curated dataset (~3B hours, ~13M patients) fuels algorithmic improvement and a structural advantage in diagnostic accuracy. This scale underpins product differentiation, partnership potential and predictive pilots, creating a durable competitive edge that supports new services and improved clinician value over time.
Negative Factors
High financial leverage
Very high leverage sharply reduces financial flexibility and increases refinancing and interest-rate risk. Even with improving cash flow, elevated debt relative to equity limits strategic optionality, raises the cost of adverse shocks, and could force dilution or curb investments if revenue or margin trends falter.
Full‑year net loss persists
Despite quarterly progress, the company remained loss‑making on a full‑year basis in 2025. Continued net losses mean profitability is not yet fully proven; rising operating expenses and conservative pricing assumptions leave earnings vulnerable to reimbursement shifts or execution slips that could reverse margin gains.
Regulatory and product timing risk
Delay of next‑gen MCT into H1 2027 and required gateway changes slow anticipated product-driven growth and prolong R&D/remediation costs. Regulatory scrutiny and evolving reimbursement dynamics raise execution risk and could defer expected revenue contributions from new form factors and features.
Irhythm Technologies (IRTC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.76B
Dividend YieldN/A
Average Volume (3M)667.93K
Price to Earnings (P/E)―
Beta (1Y)0.79
Revenue Growth25.45%
EPS Growth66.62%
CountryUS
Employees2,000
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.17
Shares Outstanding32,316,760
10 Day Avg. Volume574,339
30 Day Avg. Volume667,930
Financial Highlights & Ratios
PEG Ratio2.07
Price to Book (P/B)37.18
Price to Sales (P/S)7.60
P/FCF Ratio164.50
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue5.69
Enterprise Value/Gross Profit8.07
Enterprise Value/Ebitda-540.47
Forecast
1Y Price Target
$210.45Price Target Upside80.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.36
Revenue Forecast (FY)$875.93M
Irhythm Technologies Business Overview & Revenue Model
Company DescriptioniRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
How the Company Makes MoneyiRhythm primarily makes money by providing end-to-end remote cardiac monitoring services to healthcare providers, which include (1) supplying its Zio wearable ECG monitors (e.g., patch-based devices worn for multiple days) and (2) performing data ingestion, algorithmic analysis, and preparation of a diagnostic report that clinicians use in patient care. Revenue is generally recognized when the monitoring service is completed and the data has been processed and a report is delivered, and it is typically driven by the volume of completed studies. The company’s revenue is largely tied to reimbursement for ambulatory ECG monitoring/diagnostic services from third-party payors (e.g., Medicare and commercial insurers) and, in some cases, patient self-pay, with realized revenue affected by reimbursement rates, coverage policies, billing and collection performance, and claim denials. iRhythm also derives revenue through commercial contracts with healthcare systems and physician practices that adopt the Zio service model; these relationships support recurring utilization as clinicians order additional monitoring studies over time. Any additional specific partnership revenue details not publicly confirmed here are null.
Irhythm Technologies Earnings Call Summary
Earnings Call Date:Feb 19, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Positive
The call emphasized strong, volume‑led revenue growth (Q4 +27.1%; FY +26.2%), meaningful margin expansion and several historic profitability and free‑cash‑flow milestones, alongside clear execution on EHR integrations, primary care adoption and AI pilots. Offsetting risks include a delay to next‑gen MCT driven by FDA and gateway changes, ongoing operating expense investments and regulatory/reimbursement uncertainties. Innovative and international channels are early stage and were conservatively treated in guidance. On balance, the company demonstrated durable core growth, expanding profitability and substantial financial flexibility while acknowledging a few timing and execution risks.Q4-2025 Updates
Positive Updates
Strong Revenue Growth
Q4 2025 revenue of $208.9M, up 27.1% year-over-year; FY2025 revenue of $747.1M, up 26.2% YoY. Fifth consecutive quarter with revenue growth above 20%.
Profitability and Cash Flow Milestones
First positive quarterly net income in company history: Q4 net income $5.6M ($0.17 dil. EPS). Full-year adjusted EBITDA $68.9M (9.2% of revenue) with Q4 adjusted EBITDA $34.3M (16.4% of revenue, +470 bps YoY). Free cash flow of $14.5M in Q4 and $34.5M for FY2025; ended year with $583.8M in cash, cash equivalents and marketable securities.
Margin Expansion
Gross margin improved to 70.9% in Q4 (up 90 bps YoY) and 70.6% for the full year (up 170 bps YoY). Significant adjusted EBITDA margin expansion (Q4 16.4%; FY improvement >1,000 bps YoY).
Market Leadership in Long‑Term Continuous Monitoring
Estimated ~72% share in long-term continuous monitoring (segment growing in the high teens). Supported by clinical credibility: more than 135 scientific publications.
Zio AT Momentum and MCT Platform Positioning
Zio AT unit growth ran more than twice the company average for the year and management stated AT grew north of 50% YoY; MCT market share approximately 15%. Next‑generation MCT (21‑day wear, improved form factor and algorithms) under FDA review with expected commercial release in H1 2027.
Commercial Expansion and EHR Integration
More than one‑third of volume originated in primary care; company serves ~40,000 primary care physicians. Over 50% of volume flows through EHR‑integrated accounts; 75 of top 100 customers fully integrated. Home enrollment ~23% of U.S. volume.
Data and AI Capabilities
Nearly 3 billion hours of curated ECG data and ~13M patients in the database. Early predictive AI pilots (with Lucem Health) reported more than 85% accuracy in pre‑identifying patients with clinically relevant arrhythmias.
International and Adjacent Market Progress
Commercial presence in the U.K., select EU markets and Japan; U.K. delivered the largest quarter of volume to date. Active sleep pilots targeting the ~40M U.S. sleep apnea patients; international markets collectively run ~3M ambulatory cardiac tests annually representing a large long‑term opportunity (current share <1%).
Forward Guidance and Profitability Roadmap
2026 guidance: revenue $870M–$880M (16%–18% growth), gross margin expected to improve ~80–100 bps vs 2025, and adjusted EBITDA margin expected to expand to 11.5%–12.5% for FY2026 (Q1 adj. EBITDA margin 3%–4%).
Negative Updates
Next‑Gen MCT Timing and FDA Questions
Next‑generation MCT release pushed into first half of 2027 due to FDA questions and required move to a new mobile gateway (cybersecurity and submission updates). This delay creates timing risk for anticipated MCT revenue contributions.
Full‑Year Net Loss and Rising Operating Expenses
Full‑year 2025 net loss of $44.6M (loss of $1.39 per diluted share). Operating expenses for FY2025 were $584.7M (up 11.8% YoY); Q4 operating expenses were $145.8M versus $119.2M prior year.
Regulatory and Reimbursement Uncertainty
Industry scrutiny around chart‑derived diagnoses (CMS activity) and evolving reimbursement policies create uncertainty. Management did not include any potential upside from chart‑scraping policy shifts in guidance; Medicare dynamics are mixed (Zio Monitor rates up, AT Medicare rates slightly down).
One‑Time Collections True‑Up and Pricing Conservatism
Q4 price improvement included a one‑time collections reserve true‑up (low single‑digit millions), which management did not fully assume in 2026 guidance; 2026 pricing guidance stands roughly flat to 2025 despite some Medicare rate changes.
Limited Near‑Term Contribution from Innovative and International Channels
Innovative channel remains a small portion (low single digits of revenue) with limited visibility despite exit‑rate step‑up; international markets currently represent <1% share in target countries and are early stage — meaningful contribution expected further out (2027+).
Remaining FDA Remediation and Implementation Costs
Management indicated ongoing remediation and FDA‑related work that adds costs today (though expected to moderate over time), constraining near‑term margin upside.
MCT and Gateway Technology Tradeoffs
Decision to move to a locked mobile gateway (initially provided device rather than patient smartphone) to address cybersecurity adds development and deployment complexity and may slow broader feature rollout (patient‑device smartphone integration deferred to a later iteration).
Company Guidance
iRhythm guided full-year 2026 revenue of $870–$880 million, implying 16–18% y/y growth versus 2025 revenue of $747.1 million (2025 growth 26.2%), with first‑quarter 2026 revenue of $193–$195 million; pricing is expected to be roughly flat to 2025 while gross margin should improve ~80–100 basis points versus 2025 (FY 2025 gross margin 70.6%, Q4 70.9%). 2026 adjusted EBITDA margin is expected to expand to 11.5–12.5% (Q1 ~3–4%), up from full‑year 2025 adjusted EBITDA of $68.9 million (9.2%) and Q4 adjusted EBITDA of $34.3 million (16.4%), and free cash flow is expected to grow versus 2025’s $34.5 million (Q4 FCF $14.5 million) with FCF skewed to the second half; year‑end 2025 cash, cash equivalents and marketable securities totaled $583.8 million. The company also said international should grow slightly ahead of company averages, Zio AT and innovative channels are expected to outpace core growth (though AT in 2026 is forecasted to grow ahead of the company but below the ~2x pace seen in 2025), and management remains focused on operational leverage as it pursues a $1 billion revenue target in 2027.Irhythm Technologies Financial Statement Overview
Summary
Operations are improving (re-accelerating 2025 revenue growth, strong/improving ~70% gross margin, and a major swing to positive operating cash flow and free cash flow), but the balance sheet is a meaningful risk with very high leverage (debt far above equity) and the company remains net loss-making on a full-year basis.Income Statement
Revenue growth has re-accelerated in 2025 (6.3% vs ~0.2% in 2024), and gross margin remains strong and improving (about 70.6% in 2025 vs 68.9% in 2024). However, profitability is still the key issue: the company remains loss-making (net margin about -6.0% in 2025), even though losses narrowed meaningfully versus 2024 (net margin about -19.1%). Overall, the trajectory is improving, but earnings quality is not yet proven given continued operating losses.44
Neutral
Balance Sheet
Leverage is the primary weakness. Total debt is very high relative to equity, with debt-to-equity rising sharply from ~0.62 in 2023 to ~8.11 in 2024 and ~4.79 in 2025, signaling a much more levered capital structure. Equity is relatively thin ($153M vs $731M of debt in 2025), which reduces financial flexibility. Returns on equity are negative due to ongoing losses, though improved in 2025 versus 2024.23
Negative
Cash Flow
Cash generation improved substantially in 2025: operating cash flow turned solidly positive ($81M) versus near-breakeven in 2024 ($3M), and free cash flow swung to positive ($81M) from negative in 2024 (-$31M). This is a notable strength and reduces near-term funding pressure, although the cash flow profile has been volatile historically (negative operating and free cash flow in 2020–2023).63
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 747.14M | 591.84M | 492.68M | 410.92M | 322.82M |
| Gross Profit | 527.25M | 407.53M | 331.81M | 281.63M | 213.57M |
| EBITDA | -3.96M | -74.13M | -96.86M | -92.14M | -83.23M |
| Net Income | -44.55M | -113.29M | -123.41M | -116.16M | -101.36M |
Balance Sheet | |||||
| Total Assets | 1.02B | 931.45M | 433.14M | 448.22M | 462.97M |
| Cash, Cash Equivalents and Short-Term Investments | 583.76M | 535.55M | 133.76M | 213.14M | 239.13M |
| Total Debt | 731.18M | 736.91M | 129.82M | 131.04M | 117.71M |
| Total Liabilities | 867.30M | 840.54M | 223.05M | 208.41M | 183.45M |
| Stockholders Equity | 152.75M | 90.91M | 210.10M | 239.81M | 279.51M |
Cash Flow | |||||
| Free Cash Flow | 34.52M | -30.55M | -90.53M | -52.84M | -65.82M |
| Operating Cash Flow | 80.86M | 3.39M | -50.10M | -23.01M | -37.75M |
| Investing Cash Flow | -277.06M | -122.98M | -1.21M | -52.43M | 105.26M |
| Financing Cash Flow | 12.61M | 511.38M | 8.82M | 26.72M | -28.58M |
Irhythm Technologies Technical Analysis
Negative
116.28
Price Trends
144.78
Negative
161.17
Negative
160.76
Negative
Market Momentum
-8.88
Negative
31.64
Neutral
36.91
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRTC, the sentiment is Negative. The current price of 116.28 is below the 20-day moving average (MA) of 124.76, below the 50-day MA of 144.78, and below the 200-day MA of 160.76, indicating a bearish trend. The MACD of -8.88 indicates Negative momentum. The RSI at 31.64 is Neutral, neither overbought nor oversold. The STOCH value of 36.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IRTC.
Irhythm Technologies Risk Analysis
Irhythm Technologies disclosed 59 risk factors in its most recent earnings report. Irhythm Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Irhythm Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $3.40B | -13.83 | -21.49% | ― | 8.97% | -1024.86% | |
66 Neutral | $2.89B | 26.50 | 6.05% | ― | 7.81% | -26.32% | |
66 Neutral | $1.54B | 18.63 | 21.07% | ― | 16.81% | 34.90% | |
65 Neutral | $718.46M | 21.81 | 4.97% | ― | 1.58% | ― | |
56 Neutral | $1.60B | -95.98 | -13.44% | ― | 18.72% | 85.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $3.76B | ― | -38.33% | ― | 25.45% | 66.62% |
* Healthcare Sector Average
IRTC
Irhythm Technologies
116.28
10.42
9.84%
ITGR
Integer Holdings
84.10
-33.08
-28.23%
AXGN
AxoGen
30.78
12.63
69.59%
LIVN
LivaNova
62.19
21.82
54.05%
INSP
Inspire Medical Systems
53.72
-117.28
-68.58%
BVS
Bioventus
8.64
-1.08
-11.11%
Irhythm Technologies Corporate Events
Business Operations and StrategyExecutive/Board Changes
Irhythm Technologies appoints Jason Patten to board
Positive
Mar 12, 2026
iRhythm Holdings, Inc., a digital health specialist listed on Nasdaq under the ticker IRTC, appointed Jason Patten to its Board of Directors effective March 12, 2026. The company leverages wearable biosensors, cloud analytics, and proprietary algorithms to convert heart rhythm data into actionable clinical information, with a focus on improving outcomes through advanced cardiac monitoring.
iRhythm’s board move brings in Patten’s decades of strategic leadership in healthcare, including his current role as Executive Vice President and Head of Enterprise Strategy at UnitedHealth Group. The appointment underscores iRhythm’s push to scale profitably, expand access through primary care, and advance AI-driven, predictive care capabilities as it works toward building a billion-dollar platform grounded in clinical excellence and long-term value creation.
The most recent analyst rating on (IRTC) stock is a Buy with a $214.00 price target. To see the full list of analyst forecasts on Irhythm Technologies stock, see the IRTC Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.